Epidermal growth factor inhibitors;Les inhibiteurs des récepteurs de l'Epidermal Growth Factor (EGF)

Revue de Medecine Interne

Volumn 24, Issue 6, 2003, Pages 372-383

  Delbaldo, C ^a   Faivre, S ^a   Raymond, E ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

C225; Cetuximab ; Iressa ; OSI 774; Tarceva ; Tyrosine kinase; ZD 1839

Indexed keywords

ANGIOGENESIS INHIBITOR; CETUXIMAB; EPIDERMAL GROWTH FACTOR INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN INHIBITOR; PROTEIN TYROSINE KINASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; LIGAND BINDING; PROTEIN EXPRESSION; REVIEW;

EID: 0038480642     PISSN: 02488663     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0248-8663(03)00060-2     Document Type: Short Survey

References (73)

1. Felice G, Horvath AR, Kellie S. Tyrosine kinase activities and neoplastic transformation. Biochem Soc Trans 1990;18(1):69-72.
2. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61(2):203-12.
3. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, et al. Oncogenes and signal transduction. Cell 1991;64(2): 281-302.
4. Konopka JB, Watanabe SM, Witte ON. An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 1984;37(3):1035-42.
5. Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990;247(4944):824-30.
6. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998;92(10):3780-92.
7. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100(3):293-6.
8. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
9. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19(3):183-232.
10. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem 1990; 265(14):7709-12.
11. Velu TJ. Structure, function and transforming potential of the epidermal growth factor receptor. Mol Cell Endocrinol 1990;70(3):205-16.
12. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244(4905):707-12.
13. Bridges AJ. The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr Med Chem 1999;6(9): 825-43.
14. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19(56):6550-65.
15. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60(Suppl 1):15-23.
16. Davies DE, Chamberlin SG. Targeting the epidermal growth factor receptor for therapy of carcinomas. Biochem Pharmacol 1996;51(9): 1101-10.
17. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82(2-3):241-50.
18. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19(13):3159-67.
19. Fry DW. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: progression from reversible to irreversible inhibitors. Pharmacol Ther 1999;82(2-3): 207-18.
20. Kelloff GJ, Fay JR, Steele VE, Lubet RA, Boone CW, Crowell JA, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as potential cancer chemopreventives. Cancer Epidemiol Biomarkers Prev 1996;5(8):657-66.
21. Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8(12):1197-206.
22. Baselga J. Targeting the epidermal growth factor receptor: a clinical reality. J Clin Oncol 2001;19(18 Suppl):41S-4S.
23. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs 2000;59(4):753-67.
24. Schmidt M, Wels W. Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins. Int J Cancer 2002;97(3):349-56.
25. Liu B, Fang M, Schmidt M, Lu Y, Mendelsohn J, Fan Z. Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity. Br J Cancer 2000;82(12): 1991-9.
26. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 1999;59(8):1935-40.
27. Peng D, Fan Z, Lu Y, DeBlasio T, Scher H, Mendelsohn J. Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Res 1996;56(16):3666-9.
28. Sato JD, Kawamoto T, Le AD, Mendelsohn J, Polikoff J, Sato GH. Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1983;1(5):511-29.
29. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6(6):2166-74.
30. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McConkey DJ, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6(5):1936-48.
31. Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5(4):909-16.
32. Baselga J, Norton L, Masui H, Pandiella A, Coplan K, Miller WH, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993;85(16):1327-33.
33. Baselga J, Pfister D, Cooper MR, Cohen R, Burtness B, Bos M, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18(4):904-14.
34. Cohen R, Falcey J, Paulter V, Fetzer K, Waksal H. Safety Profile of the Monoclonal Antibody (MoAb) IMC-C225, an Anti-Epidermal Growth Factor Receptor (EGFr) Used in the Treatment of EGFr-Positive Tumors. Proc Am Soc Clin Oncol 2000;19:1862.
35. Herbst RS, Langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol 2002;29(1 Suppl 4):27-36.
36. Magne N, Pivot X, Bensadoun RJ, Guardiola E, Poissonnet G, Dassonville O, et al. The relationship of epidermal growth factor receptor levels to the prognosis of unresectable pharyngeal cancer patients treated by chemo-radiotherapy. Eur J Cancer 2001;37(17):2169-77.
37. Shin DM, Donato NJ, Perez-Soler R, Shin HJ, Wu JY, Zhang P, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7(5):1204-13.
38. Hong WK, Arquette M, Nabell L, Needle M, Waksal H, Herbst RS. Efficacy and Safety of the Anti-Epidermal Growth Factor Antibody (EGFR) IMC-C225, in Combination with Cisplatin in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN) Refractory to Cisplatin Containing Chemotherapy. Proc Am Soc Clin Oncol 2001;20:895.
39. Baselga J, Trigo J, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 2002;21:900.
40. Burtness B, Li Y, Flood W, Mattar B, Forastiere A. Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody(EGF-R) C225 in patients (pts) with metastatic/ recurrent head & neck cancer (HNC). Proc Am Soc Clin Oncol 2002;21:901.
41. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19(13): 3234-43.
42. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data, MACH-NC Collaborative Group, Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;355(9208):949-55.
43. Kim E, Mauer A, Fossella F, Jamison T, Kies M, Pisters B, et al. A phase II study of Erbitux (IMC-C225), an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel in chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2002;21:1168.
44. Rubin M, Shin D, Pasmantier M, Falcey J, Paulter V, Fetzer K, et al. Monoclonal Antibody (MoAb) IMC-C225, an Anti-Epidermal Growth Factor Receptor (EGFr), for Patients (Pts) with EGFr-Positive Tumors Refractory to or in Relapse from Previous Therapeutic Regimens. Proc Am Soc Clin Oncol 2000;19:1860.
45. Salz L, Rubin M, Hochster H, Tchekmeydian N, Waksal H, Needle M, et al. Cetuximab (IMC-C225) Plus Irinotecan (CPT-11) is Active in CPT-11-Refractory Colorectal Cancer (CRC) that Expresses Epidermal Growth Factor Receptor (EGFR). Proc Am Soc Clin Oncol 2001;20:7.
46. Salz L, Meropol N, Loehrer P, Waksal H, Needle M, Mayer R. Single agent IMC-C225 (Erbitux(tm)) has activity in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2002;21:504.
47. Abbruzzese JL, Rosenberg A, Xiong Q, LoBuglio A, Schmidt W, Wolff R, et al. Phase II Study of Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Cetuximab (IMC-C225) in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. Proc Am Soc Clin Oncol 2001;20:518.
48. Baselga J, Averbuch SD. ZD1839 ("Iressa") as an anticancer agent. Drugs 2000;60(Suppl 1):33-40.
49. Woodburn J, Kendrew J, Fennel M, Wakeling A. ZD1839 (Iressa) a selective epidermal growth factor receptor kinase inhibitor (EGFR-TKI): Inhibition of c-fos, mRNA, an intermediate marker of EGFR activation, correlates with tumor growth inhibition. Proc Am Assoc Cancer Res 2000;41:2552.
50. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6(12):4885-92.
51. Meric JB, Faivre S, Monnerat C, Adi VN, Le Chevalier T, Armand JP, et al. [Zd 1839 "Iressa"]. Bull Cancer 2000;87(12):873-6.
52. Ranson M, Hammond LA, Ferry D, Kris M, Tullo A, Murray PI, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002;20(9): 2240-50.
53. Baselga J, Herbst RS, LoRusso P, Rischin D, Ranson M, Plummer R, et al. Continuous Administration of ZD1839 (Iressa), a Novel Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Patients with Five Selected Tumor Types: Evidence of Activity and Good Tolerability. Proc Am Soc Clin Oncol 2000;19: 686.
54. Negoro S, Nakagawa K, Fukuoka M, Kudoh S, Tamura T, Takeda K, et al. Final Results of a Phase I Intermittent Dose-Escalation Trial of ZD1839 ("Iressa") In Japanese Patients With Various Solid Tumours. Proc Am Soc Clin Oncol 2001;20:1292.
55. Kris M, Herbst R, Rischin D, LoRusso P, Baselga J, Hammond L, et al. Objective regressions in non-small cell lung cancer patients treated in Phase I trials of oral ZD1839 (Iressa) a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer 2000;29:233.
56. Cohen E, Rosen F, Dekker A, Bajda C, Stenson K, Shulman K, et al. Phase II study of ZD1839 (Iressa) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc Am Soc Clin Oncol 2002;21:899.
57. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard J, et al. Final results from a phase II trial of ZD 1839 ("Iressa") for patients with advanced non-small-cell lung cancer (Ideal 1). Proc Am Soc Clin Oncol 2002;21:1188.
58. Kris M, Natale R, Herbst R, Lynch T, Prager T, Belani C, et al. A phase II trial of ZD 1839 ("Iressa") in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (Ideal 2). Proc Am Soc Clin Oncol 2002;21:1166.
59. Miller VA, Johnson D, Heelan R, Pizzo B, Perez W, Bass A, et al. A Pilot Trial Demonstrates the Safety of ZD1839 ("Iressa"), an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), in Combination with Carboplatin (C) and Paclitaxel (P) in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:1301.
60. Giaccone G, Gonzales-Larriba J, Smit E, Alfonso R, Van Oosterom A, Martens M, et al. Combinaton therapy with ZD1839 (Iressa), an orally active, selective, epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), gemcitabine and cisplatine, in patients with advanced solid tumors: promising preliminary results on tolerability, efficacy, and pharmakinetics. Proc Am Assoc Cancer Res 2001;7:553.
61. Raben D, Helfrich BA, Chan D, Johnson G, Bunn Jr. PA. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Semin Oncol 2002; 29(1 Suppl 4):37-46.
62. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 2002;13(1):65-72.
63. Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001;19(13): 3267-79.
64. Senzer N, Soulieres D, Siu L, Agarwala S, Vokes E, Hidalgo M, et al. Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Squamous Cell Carcinoma of the Head and Neck. Proc Am Soc Clin Oncol 2001;20(6).
65. Perez-Soler R, Chachoua A, Huberman M, Karp D, Rigas J, Hammond L, et al. A Phase II Trial of the Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor OSI-774, Following Platinum-Based Chemotherapy, in Patients (pts) with Advanced, EGFR-Expressing, Non-Small Cell Lung Cancer (NSCLC). Proc Am Soc Clin Oncol 2001;20:1235.
66. Finkler N, Gordon L, Crozier M, Edwards R, Figueroa J, Garcia A, et al. Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with Advanced Ovarian Carcinoma. Proc Am Soc Clin Oncol 2001;20:831.
67. Yang XD, Jia XC, Corvalan JR, Wang P, Davis CG, Jakobovits A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59(6):1236-43.
68. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94(5):1593-611.
69. Stragliotto G, Vega F, Stasiecki P, Gropp P, Poisson M, Delattre JY. Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer 1996;32A(4):636-40.
70. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A. Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody. Int J Cancer 2002;101(6):567-75.
71. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94(5):1593-611.
72. Allen LF, Lenehan PF, Eiseman IA, Elliott WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002;29(3 Suppl 11):11-21.
73. Dittrich C, Greim G, Bomer M, Weigang-Kohler K, Huisman H, Amelsberg A, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer 2002;38(8): 1072-80.